Beijing Novogene Technology Co. Ltd. cancelled the acquisition of 10 Sequel Systems, so-Seq annotation from Pacific Biosciences of California, Inc..
January 15, 2018
Share
Beijing Novogene Technology Co. Ltd. agreed to acquire 10 Sequel Systems, so-Seq annotation from Pacific Biosciences of California, Inc. (NasdaqGS:PACB) on January 16, 2017.
Beijing Novogene Technology Co. Ltd. cancelled the acquisition of 10 Sequel Systems, so-Seq annotation from Pacific Biosciences of California, Inc. (NasdaqGS:PACB) on January 16, 2018.
Novogene Co Ltd is a China-based company principally engaged in gene sequencing. The Company mainly relies on high-throughput sequencing technology and bioinformatics analysis technology to establish gene sequencing platforms. Combined with multi-omics research technology, the Company provides multi-level scientific and research technical services and solutions for life science basic research, medical and clinical application research. Based on the technology accumulation in gene sequencing and its application fields, the Company independently develops genetic testing medical equipment. The Company's services mainly include life science basic scientific research services, medical research and technical services, and database-building sequencing platform services. Its other services and products include gene mutation detection kits, coronavirus disease nucleic acid test service and DA8600 sequencers. The Company conducts its businesses in domestic and overseas markets.
NOVOGENE CO., LTD. 
